← 返回前沿论文

识别与高级别胶质瘤免疫细胞重编程相关的免疫调节性 lncRNA 特征

英文原题:Identification of an immunomodulatory lncRNA signature associated with immune cell reprogramming in high-grade glioma.

查看英文原题

Identification of an immunomodulatory lncRNA signature associated with immune cell reprogramming in high-grade glioma.

PubMed 2025/06/17(内容时间) Cancer Gene Ther Q1 · IF 6.4(JCR 2025)

研究概要

高级别胶质瘤(HGGs)是儿童、青少年和年轻成人(AYA)癌症患者中最具侵袭性的脑肿瘤之一,诊断后中位生存期为12-15个月。

中文摘要

高级别胶质瘤(HGGs)是儿童、青少年和年轻成人(AYA)癌症患者中侵袭性最强的脑肿瘤之一,诊断后中位生存期为12-15个月。其不良预后由高度免疫抑制的肿瘤免疫微环境(TIME)驱动,该微环境抑制细胞毒性免疫浸润和抗肿瘤反应。本研究使用两种小鼠模型探讨了长链非编码RNA(lncRNAs)在塑造HGGs免疫表型中的参与作用:RCAS-PDGFb代表免疫抑制性TME,RCAS-BRAF V600E则以更符合促炎性TME的特征为特点。对肿瘤浸润免疫细胞的转录组分析鉴定了与免疫抑制性和促炎性TME相关的不同lncRNA特征。单细胞RNA测序和空间转录组学支持这些lncRNAs在高等级胶质瘤相关免疫细胞(如髓系细胞、T细胞和NK细胞)中具有情境依赖性表达,并揭示了它们在胶质母细胞瘤(GBM)TME中的空间分布。若干lncRNAs在GBM患者样本的肿瘤边缘和坏死区域内富集,与免疫抑制重编程和免疫逃逸机制相关。这些发现突显了特定免疫调节性lncRNAs可能是免疫抑制性胶质瘤TME中的潜在参与者,并可能是未来旨在开发新型治疗策略以克服免疫抑制并改善临床结局的研究的候选靶点。

展开英文摘要原文

High-grade gliomas (HGGs) are among the most aggressive brain tumors in pediatric, adolescent, and young adult (AYA) cancer patients, with a median survival of 12-15 months post-diagnosis. Their poor prognosis is driven by a highly immunosuppressive tumor immune microenvironment (TIME), which inhibits cytotoxic immune infiltration and anti-tumor response. This study investigated the involvement of long non-coding RNAs (lncRNAs) in shaping the immune phenotype of HGGs using two murine models: RCAS-PDGFb representing an immunosuppressive TME, and RCAS-BRAF V600E characterized by a signature more consistent with a pro-inflammatory TME. Transcriptomic analysis of tumor-infiltrating immune cells identified distinct lncRNA signatures associated with immunosuppressive and pro-inflammatory TMEs. Single-cell RNA sequencing and spatial transcriptomics supported context-dependent expression of these lncRNAs in high-grade glioma-associated immune cells, such as myeloid, T, and NK cells, and revealed their spatial distribution within the glioblastoma (GBM) TME. Several lncRNAs were enriched at the tumor edge and within necrotic regions in GBM patient samples, correlating with immunosuppression reprogramming and immune evasion mechanisms. These findings highlight specific immunomodulatory lncRNAs as potential players in the immunosuppressive glioma TME, and likely candidates for future studies aimed at developing novel therapeutic strategies to overcome immune suppression and improve clinical outcomes.

论文信息

作者
Canella A、Rajappa P
第一作者单位
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA. alessandrocanella@ymail.com.United States
通讯作者单位
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA. prajwal.rajappa@nationwidechildrens.org.United States
期刊
Cancer gene therapy2025 Jul
原文标识
PubMed 40527978 · DOI 10.1038/s41417-025-00919-3